| NCT ID | NCT04654364 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-08-18 |
| Primary Completion | 2030-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2020-08-18 with a primary completion date of 2030-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. Therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women. This malignant disease can be divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. Despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. For these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. Until recently, little progress has been made in the treatment of SCLC in last decades. Recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced SCLC has been reported. Despite the progress in the treatment of NSCLC, the performance of predictive biomarkers is weak. Therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.
Eligibility Criteria
Inclusion Criteria: * stage III A-C and IV A-B NSCLC * limited disease (LD) and extensive disease (ED) SCLC) * patients ≥ 18 years Exclusion Criteria: \- Due to the non-interventional design of the registry there are no specific exclusion criteria.
Contact & Investigator
Richard Greil, MD
STUDY CHAIR
AGMT gemeinnützige GmbH
Frequently Asked Questions
Who can join the NCT04654364 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04654364 currently recruiting?
Yes, NCT04654364 is actively recruiting participants. Contact the research team at office@agmt.at for enrollment information.
Where is the NCT04654364 trial being conducted?
This trial is being conducted at Salzburg, Austria, Innsbruck, Austria, Linz, Austria.
Who is sponsoring the NCT04654364 clinical trial?
NCT04654364 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. The principal investigator is Richard Greil, MD at AGMT gemeinnützige GmbH. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.